Poolbeg Pharma notify that Schroders PLC increase holding to 5.13%

Poolbeg Pharma plc (LON:POLB) have today announced a TR-1: Notification of major interest in shares. The company published the note stating Schroders PLC now own 25,641,941.00 voting rights, its previous position was under the reportable threshold. This means that Schroders now hold an indirect interest of 5.128388% in Poolbeg Pharma. The transaction took place on the 18th May 2022.

Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF), is a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.

Share on:

Written by: Giles

Find more news, interviews, share price & company profile here for:
Poolbeg Pharma plc

Latest Company News

Poolbeg Pharma Making Pivotal Strides in Cancer and Metabolic Disease Innovation – Shore Capital

May 21, 2025

Poolbeg Pharma raises £4.7m through Placing and Subscription

May 21, 2025

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs.

Poolbeg Pharma launches £4.1m fundraising

May 20, 2025

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs.

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

May 20, 2025

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy.

Poolbeg Pharma targets severe flu and cytokine storms

May 19, 2025

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy.

POLB 001 targets deadly cytokine storms in cancer therapy

May 12, 2025

Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes.